Study of AK156 in Primary Osteoporosis Patients

PHASE3CompletedINTERVENTIONAL

Enrollment

600

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

January 31, 2015

Study Completion Date

January 31, 2015

Conditions

Osteoporosis

Interventions

DRUG

AK156

zoledronic acid (i.v.)/year + daily calcium and vitamin D for 2 years

DRUG

Placebo

placebo (i.v.)/year + daily calcium and vitamin D for 2 years

Trial Locations (20)

Chiba

Fukuoka

Kure

Sapporo

Inami-cho

Morioka

Kagoshima

Yokohama

Kumamoto

Sendai

Miyazaki

Matsumoto

Bungo-ōno

Tosu

Tokorozawa

Kikukawa

Oyama

Setagaya City

Shinagawa

Tonami

All Listed Sponsors

lead

Asahi Kasei Pharma Corporation

INDUSTRY

NCT01522521 - Study of AK156 in Primary Osteoporosis Patients | Biotech Hunter | Biotech Hunter